We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Combination therapy may hold the key to slowing down Alzheimer's disease
News

Combination therapy may hold the key to slowing down Alzheimer's disease

Combination therapy may hold the key to slowing down Alzheimer's disease
News

Combination therapy may hold the key to slowing down Alzheimer's disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Combination therapy may hold the key to slowing down Alzheimer's disease "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Resveratrol is a naturally occurring polyphenolic phytochemical produced in several plants, especially grapes skin and seeds. One epidemiological study reported a positive association between moderate red wine consumption and a low incidence of cardiovascular disease, known as the "French Paradox."


See Also: Large doses of antioxidants may be harmful to neuronal stem cells


The neuroprotective effects of resveratrol for the treatment of Alzheimer's disease (AD) have been investigated in various in vitro and in vivo models of AD. Despite the high bioactivity of resveratrol in AD, there is poor bioavailability of resveratrol, that is, the concentrations required producing favourable biological effects in the brain and neuronal cells are insufficient to demonstrate efficacy in humans. Therefore, successful clinical application of resveratrol as a single 'take home' oral therapy alone presents a major challenge for the treatment of AD.


The researchers of the work propose a novel combination therapy consisting of an agent for chelating redox-active metals (Fe2+) and/or an antioxidant to reduce damage caused by residual oxygen free radicals, in addition to resveratrol, a modulator of AMPK and sirtuin pathways (nuclear transcription).


Learn More: Brain injuries in mice treated using bone marrow stem cells, antioxidants


The addition of resveratrol may have the capacity to increase activity of the NAD+-dependant deacetylases such as sirtuin family enzymes (e.g. SIRT1) and promote improved DNA repair by enhancing PARP enzyme activity through increased production of their essential substrate NAD+, and thus improve cell viability and longevity. A synergistic combination of a selected antioxidant substances, Fe2+ chelating agents and resveratrol may be expected to provide a more clinically successful treatment.


Note: Material may have been edited for length and content. For further information, please contact the cited source.


Bentham Science Publishers


Publication

Braidy N et al. Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer’s Disease.  Current Topics in Medicinal Chemistry, Published 2016. doi: 10.2174/1568026616666160204121431


Advertisement